This protocol applies to patients with Multiple endocrine neoplasia type 2A (MEN2A) who have developed painful bone metastases originating from medullary thyroid carcinoma. Osseous involvement in this context produces significant pain and poses risk of further skeletal complications.
Bone metastases from medullary thyroid carcinoma are an established clinical challenge in MEN2A. Managing pain and reducing the risk of skeletal-related events are recognised priorities. Treatment with denosumab or bisphosphonates is recommended for patients with painful osseous metastases.
A bone-targeted pharmacological intervention forms the basis of management — the specific agent and complete selection criteria are defined in the full protocol.
DOI: 10.1089/thy.2014.0335
Treatment with denosumab or bisphosphonates is recommended for patients with painful osseous metastases.
Treatment with either intravenous bisphosphonates (zoledronic acid or pamidronate) or the receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, denosumab, in patients with thyroid cancer has been effective in relieving pain from bony metastases and in preventing or delaying the occurrence of other skeletal related events.
View source ↗